Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
PDE3A is a low-affinity and high-velocity enzyme for hydrolysis of cUMP in cardiac myocytes.
PDE3A is the primary isozyme modulating basal myocardial contractility and sarcoplasmic reticulum divalent calcium ion (Ca2 (show CA2 Proteins)+) content.
Discussion of role of PDE3A, not PDE3B, in cell cycle progression in vascular smooth muscle and oocytes via regulation of cAMP levels. Is inhibition of PDE3A a possible target for treatment of cardiovascular diseases or female infertility? [REVIEW]
PDE3A regulates VSMC growth via two complementary pathways
phosphodiesterase-III inhibitor prevents the hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA (show PLAT Proteins)
Results provide evidence indicating that resumption of meiosis in vivo and in vitro requires cyclic nucleotide phosphodiesterase 3A activity.
These data indicate that activation of PDE3A by PKB/Akt (show AKT1 Proteins)-mediated phosphorylation plays a role in the control of PDE3A activity in mammalian oocytes.
Role of Pde3a in regulating platelet and cardiac function using subtype-selective knockout mice is reported.
Gpr3 (show GPR3 Proteins) is epistatic to Pde3a and fertility as well as meiotic arrest in the PDE3A-deficient oocyte is dependent on the activity of GPR3 (show GPR3 Proteins).
Vulnerability to antineoplastic phosphodiesterase inhibitors inhibitors has been associated with co-expression of PDE3A and SLFN12 in various tumor types.
We found a novel heterozygous missense mutation c.1336T>C in exon 4 of the PDE3A gene in a Japanese family with multiple HTNB patients. This mutation was found to be completely linked to the family members who inherited this condition.
The genetic variant, rs3794271, located within the PDE3A-SLCO1C1 (show SLCO1C1 Proteins) locus was analyzed for correlation with treatment response using both the EULAR classification criteria and absolute change in (Delta)DAS28 scores as outcome measures correlated with anti-TNF (show TNF Proteins) response in a large UK rheumatoid arthritis cohort.
Chemical proteomics results show that besides known interactors such as 14-3-3 (show YWHAQ Proteins) family proteins, PDE3A was found to associate with a PP2A (show PPP2R4 Proteins) complex composed of a regulatory, scaffold and catalytic subunit.
We found a highly significant association between PDE3A-SLCO1C1 (show SLCO1C1 Proteins) and the clinical response to TNF (show TNF Proteins) blockers
A heterozygous missense mutation in PDE3A causes autosomal dominant hypertension with brachydactyly.
PDE3A is part of a SERCA2 (show ATP2A2 Proteins) signaling complex in cardiac myocytes.
the genotypic and allelic frequencies of the rs7134375 SNP are different between the Mulao and Han populations. the PDE3A rs7134375 SNP is associated with serum TG levels in the Mulao population, however, not in the Han population.
The PDE3A-SLCO1C1 (show SLCO1C1 Proteins) locus rs3794271 SNP showed a highly significant association with anti-TNF (show TNF Proteins) treatment response.
Data show that PDE3A inhibition augments CFTR-dependent submucosal gland secretion and actin skeleton disruption decreases secretion.
Results demonstrated that PDE3A is the major cAMP-degrading PDE (show TWIST1 Proteins) in the oocyte.
Degradation of the intracellular cyclic nucleotide by Pde3a is transcriptionally up-regulated via a cAMP-dependent pathway in cumulus cells, suggesting that it has a functional role during the ovulatory gonadotropin surge.
This gene encodes a member of the cGMP-inhibited cyclic nucleotide phosphodiesterase (cGI-PDE) family. cGI-PDE enzymes hydrolyze both cAMP and cGMP, and play critical roles in many cellular processes by regulating the amplitude and duration of intracellular cyclic nucleotide signals. The encoded protein mediates platelet aggregation and also plays important roles in cardiovascular function by regulating vascular smooth muscle contraction and relaxation. Inhibitors of the encoded protein may be effective in treating congestive heart failure. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
phosphodiesterase 3A, cGMP-inhibited
, cGMP-inhibited 3',5'-cyclic phosphodiesterase A
, phosphodiesterase 3a
, cGMP-inhibited 3',5'-cyclic phosphodiesterase A-like
, CGI-PDE A
, cGMP-inhibited phosphodiesterase
, cyclic GMP-inhibited phosphodiesterase A
, cyclic nucleotide phosphodiesterase
, cAMP phosphodiesterase, myocardial cGMP-inhibited